Side effects are rare. Some reported adverse events include changes in color vision, blood clots, and allergic reactions such as anaphylaxis. Whether the risk of venous thromboembolism (blood clots) is actually increased is a matter of debate. The risk is mentioned in the product literature, and they were reported in post marketing experience. Despite this, and the inhibitory effect of<unk>  on blood clot breakdown, large studies of the use of<unk>  have not shown an increase in the risk of venous or arterial thrombosis, even in people who had previously experienced thrombosis under other circumstances. Special populations *<unk>  is categorized as pregnancy category B. No harm has been found in animal studies. * Small amounts appear in breast milk if<unk> ken during lactation. If it is required for other reasons, breastfeeding may be continued. * In kidney impairment,<unk>  is not well studied. However, due to the fact that it is 95% excreted unchanged in the urine, it should be dose adjusted in patients with renal impairment. * In liver impairment, dose change is not needed as only a small amount of the drug is metabolized through the liver.
Tranexamic acid
Platelet-rich plasma
Flufenamic acid
Heparin
Hirudin
Palladin
Celadrin 
Tinzaparin sodium